Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 2/20 | 0.69 |
| ▸ | DRD2 | P14416 | 1/20 | 0.64 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.64 |
| ▸ | HTR2A | P28223 | 10/20 | 0.61 |
| ▸ | DRD3 | P35462 | 9/20 | 0.61 |
| ▸ | HTR7 | P34969 | 1/20 | 0.55 |
| ▸ | HTR2C | P28335 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2461661 | 1.00 | ACHE (0.69) | ACHEDRD2SLC6A4HTR2ADRD3 | |
| SCHEMBL2457949 | 0.86 | ACHE (0.74) | ACHEDRD2SLC6A4HTR2ADRD3 | |
| SCHEMBL2457950 | 0.86 | ACHE (0.74) | ACHEDRD2SLC6A4HTR2ADRD3 | |
| SCHEMBL2465861 | 0.84 | ACHE (0.75) | ACHEDRD2SLC6A4HTR2ADRD3 | |
| SCHEMBL2465862 | 0.84 | ACHE (0.75) | ACHEDRD2SLC6A4HTR2ADRD3 | |
| SCHEMBL1545611 | 0.83 | ACHE (0.93) | ACHEDRD2SLC6A4HTR2ADRD3 | |
| SCHEMBL3249919 | 0.82 | ACHE (0.71) | ACHEDRD2SLC6A4HTR2ADRD3 | |
| SCHEMBL28504239 | 0.82 | ACHE (0.71) | ACHEDRD2SLC6A4HTR2ADRD3 | |
| SCHEMBL604085 | 0.82 | ACHE (0.71) | ACHEDRD2SLC6A4HTR2ADRD3 | |
| SCHEMBL9532457 | 0.81 | ACHE (0.77) | ACHEDRD2SLC6A4HTR2ADRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8541585-B2 | N-acyl cyclic amine derivative or pharmaceutically acceptable salt thereof | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2013-09-24 | — | — | US | disclosed |
| US-8541585-B2 | N-acyl cyclic amine derivative or pharmaceutically acceptable salt thereof | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2013-09-24 | — | — | US | disclosed |
| US-8541585-B2 | N-acyl cyclic amine derivative or pharmaceutically acceptable salt thereof | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2013-09-24 | — | — | US | disclosed |
| EP-2545046-A1 | N-ACYL CYCLIC AMINE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2013-01-16 | — | — | EP | disclosed |
| US-20120214790-A1 | N-ACYL CYCLIC AMINE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | DAINIPPON SUMITOMO PHARMA CO., LTD. | 2012-08-23 | — | — | US | disclosed |
| US-20120214790-A1 | N-ACYL CYCLIC AMINE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | DAINIPPON SUMITOMO PHARMA CO., LTD. | 2012-08-23 | — | — | US | disclosed |
| US-20120214790-A1 | N-ACYL CYCLIC AMINE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | DAINIPPON SUMITOMO PHARMA CO., LTD. | 2012-08-23 | — | — | US | disclosed |
| WO-2011111875-A1 | N-ACYL CYCLIC AMINE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2011-09-15 | — | — | WO | disclosed |
| WO-2011111875-A1 | N-ACYL CYCLIC AMINE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2011-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120214790-A1 | N-ACYL CYCLIC AMINE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | GRIN2C, GRIN2A, GRIN2B | ACHE 1009/4885DRD2 25/4885SLC6A4 189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.